These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 9814459)

  • 1. Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender.
    Indridason OS; Pieper CF; Quarles LD
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3860-6. PubMed ID: 9814459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients.
    Marco MP; Martínez I; Amoedo ML; Borràs M; Saracho R; Almirall J; Fibla J; Fernández E
    Kidney Int; 1999 Oct; 56(4):1349-53. PubMed ID: 10504487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
    Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
    Alghareeb A; Sabry A; Bawadekji H; Alsaran K
    Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of calcium-channel blockers on calcium-phosphate metabolism in patients with end-stage renal disease.
    Lippuner K; Zehnder HJ; Casez JP; Takkinen R; Descoeudres C; Jaeger P
    Nephrol Dial Transplant; 1996 Jan; 11(1):70-4. PubMed ID: 8649655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic follow-up of the intact parathormone levels in hemodialysis patients treated with Rocaltrol and calcium.
    Dimitrakov D; Koumtchev E; Dimitrova R; Stavrev P
    Folia Med (Plovdiv); 1998; 40(4):48-53. PubMed ID: 10371800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
    Takahashi Y; Tanaka A; Nakamura T; Fukuwatari T; Shibata K; Shimada N; Ebihara I; Koide H
    Kidney Int; 2004 Mar; 65(3):1099-104. PubMed ID: 14871431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
    Navarro JF; Mora C; Macia M; Garcia J
    Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of vitamin C on parathyroid hormone in hemodialysis patients with mild to moderate secondary hyperparathyroidism.
    Sanadgol H; Bayani M; Mohammadi M; Bayani B; Mashhadi MA
    Iran J Kidney Dis; 2011 Nov; 5(6):410-5. PubMed ID: 22057074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A; Naderi AS
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
    Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
    Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.